The wind whips across the North Sea, a constant, bracing reminder of nature's formidable power. For Kjersti Haugland, this environment, one she navigated for years in Norway's demanding oil and gas industry, was not merely a backdrop but a classroom. It taught her resilience, precision, and the critical importance of robust engineering in high-stakes environments. Now, she applies these lessons not to drilling platforms, but to the delicate intricacies of human respiration, leading Medsensio, a company poised to revolutionize chronic obstructive pulmonary disease, or Copd, diagnostics and management with artificial intelligence.
Haugland's defining moment, perhaps, was not a singular event but a gradual realization. After years spent optimizing complex systems in a sector synonymous with large-scale industrial operations, she observed a stark contrast in healthcare. While industrial processes were increasingly data-driven and predictive, medical diagnostics, particularly for chronic conditions, often lagged, relying on episodic measurements and subjective interpretation. This incongruity struck her as an opportunity, a chance to apply the rigorous, data-centric approach of her past to a field where human lives hung in the balance.
Born and raised in Stavanger, Norway, a city deeply intertwined with the nation's energy sector, Haugland's early life was steeped in a culture that values engineering excellence and practical problem-solving. Her academic journey led her to the Norwegian University of Science and Technology, Ntnu, in Trondheim, where she earned a Master of Science degree in Industrial Economics and Technology Management. This interdisciplinary background, blending technical depth with economic foresight, proved foundational. It equipped her with a holistic perspective, understanding not just how to build innovative technology, but also how to scale it and integrate it into existing systems effectively. After graduation, she spent over a decade at Schlumberger, a global leader in oilfield services, rising through the ranks and gaining invaluable experience in project management, operational efficiency, and international business development. This period honed her leadership skills and instilled a profound appreciation for data integrity and analytical rigor.
The genesis of Medsensio, however, required a pivot, a conscious decision to transition from one complex domain to another. The inspiration, as it often is, was deeply personal. Observing the struggles of individuals with chronic respiratory conditions, she recognized the urgent need for better, more continuous monitoring. Traditional spirometry tests are often performed infrequently and in clinical settings, failing to capture the day-to-day fluctuations that define chronic illness. This led her to a critical insight: what if we could bring sophisticated, continuous monitoring directly to the patient's home, leveraging the power of AI to interpret the subtle signals of deteriorating health?
This vision led her to meet her co-founder, Dr. Jan-Are Kolseth, a medical doctor and researcher with a background in respiratory physiology. Their collaboration was a classic synergy of complementary skills. Haugland brought the engineering discipline and business acumen, while Kolseth provided the clinical expertise and deep understanding of respiratory diseases. Together, they formed Medsensio in 2017, driven by a shared conviction that technology could fundamentally improve the lives of millions suffering from conditions like Copd.
The breakthrough for Medsensio lay in its innovative approach to acoustic sensing and AI. Instead of relying on bulky, expensive hospital equipment, they developed a compact, non-invasive device that patients could use at home. This device, roughly the size of a smartphone, captures subtle acoustic patterns from the patient's breathing. "Let me explain the engineering," Haugland might say, detailing how these raw acoustic signals are then fed into proprietary machine learning algorithms. These algorithms are trained on vast datasets of respiratory sounds, learning to identify patterns indicative of exacerbations, infections, or changes in lung function long before they become critical. It is akin to a highly trained ear, listening for the faintest whisper of trouble in the body's internal symphony.
Building Medsensio was not without its challenges. The healthcare sector is notoriously complex, with stringent regulatory hurdles and a conservative adoption curve for new technologies. Hiring a team that blended medical professionals, data scientists, and hardware engineers was crucial. Haugland emphasized a culture of meticulous validation, ensuring that every algorithmic prediction was rigorously tested against clinical outcomes. This commitment to evidence-based development is a hallmark of Norway's approach to AI, rooted in trust.
Funding followed the promise of their technology. Medsensio successfully raised capital from a combination of private investors, including Norwegian venture capital firms, and public grants from Innovation Norway, a state-owned company promoting Norwegian innovation. These funds fueled further research and development, clinical trials, and market expansion. By early 2026, Medsensio had secured partnerships with several major healthcare providers in Scandinavia and was initiating pilot programs in other European markets. Their device had received CE mark certification, a critical regulatory milestone for medical devices within the European Economic Area.
Today, Medsensio stands as a testament to Haugland's vision. The company's technology is not merely a diagnostic tool, but a continuous companion for patients, providing real-time insights to clinicians and empowering individuals to manage their conditions more proactively. The data collected by Medsensio's devices offers a granular, longitudinal view of a patient's respiratory health, enabling personalized treatment plans and potentially reducing hospital readmissions. This proactive, preventative model aligns perfectly with the broader shift towards value-based care in healthcare.
What drives Kjersti Haugland is a profound sense of purpose. It is not just about building a successful company, but about leveraging Norway's engineering heritage and commitment to social welfare to create tangible improvements in global health. Her work exemplifies how the Nordic model extends to technology, prioritizing solutions that benefit society at large. "Our goal is to move beyond episodic care to continuous, predictive health management," Haugland stated in a recent interview with a Nordic tech publication. "We want to give patients and doctors the information they need, when they need it, to prevent crises rather than just react to them." This perspective resonates deeply with the preventative healthcare philosophies gaining traction globally, as evidenced by discussions on AI's role in drug discovery and precision medicine, as explored in articles like Finland's Quiet Revolution: How AI and Crispr Could Redefine Precision Medicine, Beyond the Hype [blocked].
The next chapter for Medsensio involves expanding their geographic footprint, particularly into markets with high burdens of respiratory disease, and broadening the scope of conditions their platform can monitor. They are also exploring integration with telemedicine platforms, further enhancing the accessibility of their insights. The ambition is clear: to make Medsensio's AI-powered respiratory monitoring a standard of care, transforming how millions navigate chronic lung conditions. From the strategic depths of oil and gas to the life-affirming frontiers of medical AI, Kjersti Haugland is charting a course that is both deeply Norwegian and globally transformative, proving that even the most complex health challenges can yield to persistent innovation and a clear, data-driven vision. The fjords may be tranquil, but the innovation emanating from Norway is anything but static. For more insights into how AI is shaping the future of healthcare, one might consult resources such as Reuters Technology. The journey of Medsensio is a compelling narrative of technical prowess meeting human empathy, a truly modern saga of progress.
